In VivoThe biotechnology sector faces an unprecedented convergence of challenges that has fundamentally altered the industry landscape. Capital availability has contracted dramatically across all traditional
ScripAnalyst reactions to Altimmune’s Phase IIb data for dual GLP-1/GIP receptor agonist pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) were mixed as the candidate showed ability to
In VivoThe phenomenal success of glucagon-like peptide-1 (GLP-1) receptor agonists in treating diabetes and obesity has sparked a wave of clinical investigations into their potential applications far beyond
ScripStock market turmoil due to macroeconomic uncertainty and biopharmaceutical industry-specific concerns have made it more difficult for publicly traded drug developers to pursue follow-on public offeri